Stockholm, 2014-10-10 13:00 CEST (GLOBE NEWSWIRE) --
Episurf Medical’s new product, Episealer® Trochlea, is based on the company’s personalized implants. It is intended to treat cartilage defects in the area behind the patella (kneecap). The product now has CE-certification and we will start offering it to selected clinics immediately, via a CPL. The company’s first product, its personalized Episealer® Femoral Condyle, has been in a CPL for the past year.
“Over the past year, we’ve affiliated major clinics and key opinion leaders to the ongoing CPL of our first product, Episealer® Femoral Condyle. Accordingly, we’ve already secured valuable contacts and launched a model that we can also use to bring this new product to market,” continued Nina Bake.
To date, 15 clinics in nine countries have affiliated to the CPL, which commenced in fall 2013. In recent months, the company has also established an international marketing and sales function, with three experienced professionals. These individuals are now gaining another product to offer clinics around Europe.
In surgery performed to date, patients rapidly regain mobility and freedom from previous pain. The first two products target patients with cartilage injury in the knee joint and the area behind the patella. This treatment is addressing a growing need, with a rising patient population experiencing knee pain and limited mobility, who often go on to develop arthrosis.
Episurf Medical has developed unique, patented technology to manufacture personalized implants and surgical tools to treat injury to human joints. The implants replace areas of damaged cartilage and skeletal tissue.
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act. For more information, go to the company’s website: www.episurf.com
For more information, please contact:
Nina Bake, CEO of Episurf Medical AB (publ)
Tel: +46 (0)73 612 5563, e-mail: ir@episurf.com
